<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00704548</url>
  </required_header>
  <id_info>
    <org_study_id>08014</org_study_id>
    <nct_id>NCT00704548</nct_id>
  </id_info>
  <brief_title>Antihypertensive Effect of Simvastatin in Hypertensive Patients</brief_title>
  <official_title>Antihypertensive Effect of Simvastatin in Hypertensive Patients: a Randomized Clinical Trial With Ambulatory Blood Pressure Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <brief_summary>
    <textblock>
      Few trials have investigated the hypotensive effect of the Statins. Most were not
      specifically aimed at this pleiotropic effect or had methodological problems. The possible
      hypotensive effect may explain part of the favorable results of the Statins use on
      cardiovascular prevention independently from its action on the cholesterol profile.

      The purpose of this study is to determine the effect of Simvastatin on the blood pressure
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized double blind parallel clinical trial where hypertensive patients with
      controlled or uncontrolled blood pressure and without evidence of target-organ damage will be
      selected. Subjects will receive Simvastatin 40 mg once daily or placebo and a baseline and
      eight weeks ABPM will performed. The main outcome will be the difference in systolic BP in
      the 24h-ABPM.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <primary_completion_date type="Anticipated">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Pressure measured with 24-Ambulatory Blood Pressure Monitoring (24h-ABPM)</measure>
    <time_frame>Eigth weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Simvastatin 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin 40mg</intervention_name>
    <description>Simvastatin once daily, orally in the morning period, during eigth weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily, orally in the morning period, during eigth weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypertensive patients with controlled or uncontrolled blood pressure

        Exclusion Criteria:

          -  Secondary causes of hypertension;

          -  Systolic Blood pressure &gt;= 180 mmHg and/or diastolic blood pressure &gt;= 110 mmHg

          -  Complain of side effects related to Statins

          -  Diabetes

          -  Established target-organ damage (myocardial infarction, stroke, angina, heart failure,
             peripheral vascular disease)

          -  Renal disease (creatinine &gt; 1,5 mgdl).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Gus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clinicas de Porto Alegre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miguel Gus, MD</last_name>
    <phone>+55512101-8420</phone>
    <email>mgus@terra.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Gus, MD</last_name>
      <phone>+55512101-8420</phone>
      <email>mgus@terra.com.br</email>
    </contact>
    <investigator>
      <last_name>Miguel Gus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2008</study_first_submitted>
  <study_first_submitted_qc>June 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2008</study_first_posted>
  <last_update_submitted>June 25, 2009</last_update_submitted>
  <last_update_submitted_qc>June 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2009</last_update_posted>
  <responsible_party>
    <name_title>Miguel Gus</name_title>
    <organization>Hospital de Cl√≠nicas de Porto Alegre</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

